These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27618361)

  • 21. PET/CT Assessment of Follicular Lymphoma and High Grade B Cell Lymphoma - Good Correlation with Clinical and Histological Features at Diagnosis.
    Novelli S; Briones J; Flotats A; Sierra J
    Adv Clin Exp Med; 2015; 24(2):325-30. PubMed ID: 25931367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
    Herold M; Schulze A; Niederwieser D; Franke A; Fricke HJ; Richter P; Freund M; Ismer B; Dachselt K; Boewer C; Schirmer V; Weniger J; Pasold R; Winkelmann C; Klinkenstein C; Schulze M; Arzberger H; Bremer K; Hahnfeld S; Schwarzer A; Müller C; Müller C;
    J Cancer Res Clin Oncol; 2006 Feb; 132(2):105-12. PubMed ID: 16088404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma.
    Herrmann K; Wieder HA; Buck AK; Schöffel M; Krause BJ; Fend F; Schuster T; Meyer zum Büschenfelde C; Wester HJ; Duyster J; Peschel C; Schwaiger M; Dechow T
    Clin Cancer Res; 2007 Jun; 13(12):3552-8. PubMed ID: 17575218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment outcome in primary testicular non-Hodgkin lymphoma].
    Iványi JL; Marton E; Plander M; Engert ZV; Tóth C
    Orv Hetil; 2013 Oct; 154(42):1666-73. PubMed ID: 24121219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral cyclophosphamide therapy for patients with residual or relapsed indolent-type lymphoma after initial treatment for aggressive lymphomas. A sub-group of patients with apparent transformed indolent lymphoma.
    Riccioni R; Galimberti S; Cervetti G; Fazzi R; Caracciolo F; Petrini M
    Leuk Lymphoma; 2002 Sep; 43(9):1803-6. PubMed ID: 12685835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphoma: diagnosis, staging, natural history, and treatment strategies.
    Zinzani PL
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S4-10. PubMed ID: 15786020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Leukemization of follicular lymphoma: The features of diagnostic and clinical course of a rare form of the disease].
    Nesterova ES; Kravchenko SK; Mangasarova YK; Plastinina LV; Dvirnyk VN; Kovrigina AM; Shchupletsova IA; Obukhova TN; Gemdzhian EG; Vorobyev IA; Vorobyev AI
    Ter Arkh; 2017; 89(7):45-50. PubMed ID: 28766540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
    Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
    J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
    Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinicopathologic features of lymphoplasmacytic lymphoma].
    Liu EB; Zhang PH; Li ZQ; Sun Q; Yang QY; Fang LH; Sun FJ; Qiu LG
    Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):308-12. PubMed ID: 20654153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma.
    Economopoulos T; Fountzilas G; Pavlidis N; Kalantzis D; Papageorgiou E; Christodoulou C; Hamilos G; Nicolaides C; Dimopoulos M
    Hematol J; 2003; 4(2):110-5. PubMed ID: 12750729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.
    Zinzani PL; Gandolfi L; Broccoli A; Argnani L; Fanti S; Pellegrini C; Stefoni V; Derenzini E; Quirini F; Baccarani M
    Cancer; 2011 Mar; 117(5):1010-8. PubMed ID: 20960498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can we cure indolent lymphomas?
    Cabanillas F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2655-9. PubMed ID: 10068269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].
    Oriuchi N; Higuchi T; Endo K; Tsukamoto N; Matsuda H; Kuji I; Murakami K; Nakajima K
    Kaku Igaku; 2009 Jun; 46(2):96-9. PubMed ID: 19637820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
    Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
    Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
    Tsujikawa T; Otsuka H; Morita N; Saegusa H; Kobayashi M; Okazawa H; Nishitani H
    Ann Nucl Med; 2008 Jan; 22(1):23-30. PubMed ID: 18250984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low grade follicular lymphoma with high proliferation index; diagnostic and management issues.
    Das S; Basu D; Dubashi B; Jain A
    Indian J Pathol Microbiol; 2012; 55(4):516-8. PubMed ID: 23455792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
    Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
    Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma.
    Ford CD; Gabor F; Morgan R; Dabbas B
    Clin Nucl Med; 2006 Jul; 31(7):391-3. PubMed ID: 16785805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.